A new Consumer Reports investigation of infant formulas found that some of the products tested contained potentially harmful ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.